The Life Sciences team advised the closing of Bicara Therapeutics’ upsized initial public offering at an approximate value of $362 million. The shares began trading on the Nasdaq Global Market on September 13, 2024. Bicara Therapeutics sold 20,125,000 shares of common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead asset, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need.
The Goodwin team was led by Gaby Morales-Rivera, Amarilice Young, Chris Huntsman, Ryan Donahoe, Jo-an Chen, and Kingsley Taft; and included Jennifer Fay, Steve Tjoe, Matt Wetzel, Grace Wirth, Zoe Li, and Anna Roy; with invaluable assistance from Li Chang, Alexa Folco, Frank Qin, Nathan Needle, Alex Denniston, and Maggie Wong.
For further details on the closing, please read the press release.